Generated by AI
Evaxion A/S American Depositary Share represents ownership in Evaxion A/S, a Denmark-based clinical-stage biotechnology company focused on AI-immunology powered vaccines. The company develops artificial intelligence-driven solutions for discovering and designing vaccines and immunotherapies aimed at cancer and infectious diseases. Its current work centers on using proprietary platforms to analyze immune-system data and support the creation of vaccine candidates for oncology, bacterial disease, and viral disease applications. Evaxion operates as a techbio company at the intersection of biotechnology and artificial intelligence, combining computational methods with immunology research to advance drug discovery. Through its American Depositary Shares, investors gain access to a company whose business is built around vaccine development and immune-based therapeutic research in the global healthcare market.
WebsiteDr. Neergaards Vej
Horsholm, 2970
Denmark
The latest articles about EVAX.
2026-11-01. The following slide deck was published by Evaxion A/S in conjunction with this event.
Detailed price information for Evaxion A/S ADR (EVAX-Q) from The Globe and Mail including charting and trades.
Summary of Oct 23's posts. Generated by AI.
Summary of Aug 20's posts. Generated by AI.
Summary of Oct 23's posts. Generated by AI.
Investors talking about EVAX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.